Acquired hemophilia A: Is more better?

Blood

Volumn 109, Issue 5, 2007, Pages 1793-1794

  Gill, Joan Cox ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; HEMOSTATIC AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; STEROID;

BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; HEMOPHILIA A; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MORBIDITY; MORTALITY; NOTE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 33847402761     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-061960     Document Type: Note

References (3)

1. Gawryl MS, Hoyer LS. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60:1103-1109.
2. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 1981;45:200-203.
3. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753-757. 1794-1795